. 2021 Sep 21;11(9):e053325. doi: 10.1136/bmjopen-2021-053325

Table 1.

Schedule of assessments performed at each observation point

Observation items	Registration	Study intervention period‡									Disconti nuation
Observation items	Registration	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 14	Disconti nuation
1. Eligibility	^〇*
2. Patients’ characteristics	^〇*
3. Severity of COVID-19 pneumonia	^〇*, †									^〇	^〇
4. Vital signs	^〇*, †				^〇				^〇	^〇	^〇
5. Quantity of oxygen administration	←				^〇	←					^〇
6. PCR test for SARS-CoV-2	^〇*, †				^〇				^〇		^〇
7. Haematology tests	^〇*, †				^〇				^〇	^〇	^〇
8. General blood biochemical tests	^〇*, †				^〇				^〇	^〇	^〇
9. Blood coagulation tests	^〇*, †				^〇				^〇	^〇	^〇
10. Chest radiography and CT	^〇*, †				△				△	^〇	^〇
11. Nasal drip tests	^〇*				^〇				^〇	^〇	^〇
12. Special blood tests	^〇*				^〇				^〇	^〇	^〇
13. Medication adherence of study agent		^〇	^〇	^〇	^〇	^〇	^〇	^〇	^〇
14. Medications of other pharmaceutical agents	←					^〇	←
15. Meal intake	←					^〇	←
16. Subjective symptoms	←					^〇	←
17. Adverse events	←					^〇	←
18. Preservation of blood serum	^〇*				^〇				^〇	^〇	^〇

〇=mandatory item; △=optional item.

*Data should be obtained before the administration of the study agent in the group A or B.

†Data obtained within 72 hours before consenting can be used in the all groups.

‡Length of hospital stay can be changed based on the subjects’ disease condition.